Lenire Tinnitus Treatment in Louisiana: How It Works, Who Qualifies, and What Results to Expect

If you live in Louisiana and have chronic ringing, buzzing, or hissing in your ears, you may have heard about Lenire. This guide explains what Lenire is, how it works, whether you might qualify, what it costs, and what to expect during and after treatment. All numbers and clinical claims come from peer-reviewed studies and the U.S. Food and Drug Administration. Nothing on this page is a diagnosis or a promise. Your candidacy has to be confirmed in person.

1. What Lenire actually is

Lenire is a small at-home medical device that treats chronic subjective tinnitus in adults. It is made by Neuromod Devices, an Irish medical device company. The system has three parts: bone-conduction headphones that play a personalized sound program, a small handheld controller, and a mouthpiece called Tonguetip that delivers mild electrical pulses to the tip of the tongue.

During a session, the sound program and the tongue stimulation happen at the same time in a carefully timed pattern. Patients use the device 30 to 60 minutes per day for 12 weeks. The Tonguetip stays on the surface of the tongue, does not pierce anything, and does not require any surgery.

Lenire is not a hearing aid. It does not amplify sound. It does not mask tinnitus while you use it. What it does is retrain the parts of the brain that keep tinnitus in the foreground, so that over the 12-week protocol most patients report the tinnitus becomes quieter and less bothersome. Those changes have been shown to hold up for at least 12 months after treatment ends.

2. How bimodal neuromodulation works

The idea behind Lenire comes from decades of research on how the brain processes sound and touch together. In healthy hearing, the brain constantly filters out background noise. In tinnitus, this filtering breaks down. Certain brain areas keep firing as if a sound is present when there is no external source.

Bimodal neuromodulation means the treatment uses two senses at once. Lenire pairs an auditory input, sound through headphones, with a somatosensory input, mild electrical pulses on the tongue. The pairing is timed so the brain treats the two signals as connected. Over weeks of daily use, this timed pairing changes how the auditory cortex and related areas respond. In animal studies going back to the early 2010s, this kind of paired stimulation reduced abnormal neural activity linked to tinnitus. In human trials with Lenire, patients reported real, measurable drops in tinnitus severity.

Two things matter about the mechanism. First, Lenire is not "just white noise." The sound program is personalized to each patient's hearing profile. Second, the tongue stimulation is central. TENT-A3, the pivotal trial that supported FDA approval, showed that bimodal stimulation produced greater tinnitus relief than sound therapy alone.

3. The FDA clearance story

In March 2023, the U.S. Food and Drug Administration granted Lenire a De Novo authorization under regulatory number DEN210033. That decision made Lenire the first and only FDA-authorized bimodal neuromodulation device for treating chronic subjective tinnitus in adults 18 and older. You can read the full FDA decision summary at accessdata.fda.gov.

A De Novo authorization is not the same as being FDA "approved" the way a new drug is approved, and it is not the same as 510(k) clearance. De Novo is used when a device is low-to-moderate risk but has no earlier device to compare against, so the FDA creates a new category. For Lenire, that new category is "external upper limb tremor stimulator" was not the classification. Lenire's classification is a bimodal neuromodulation device intended to provide temporary tinnitus relief. In plain language, the FDA reviewed the safety data and the pivotal trial results and agreed the device does what Neuromod says it does, safely, when used as directed.

The clearance was based on three large clinical trials that we describe next.

4. Who qualifies for Lenire

Lenire has clear candidacy criteria. Meeting them requires an in-person screening with a certified provider. In general, a good Lenire candidate is someone who:

• Is 18 years of age or older
• Has had subjective tinnitus for at least 3 months
• Scores at least moderate severity on the Tinnitus Handicap Inventory (THI 38 or higher) or Tinnitus Functional Index (TFI 25 or higher)
• Does not have an active middle-ear infection, a perforated eardrum in the acute phase, or Meniere's disease in an active flare
• Does not have an active implanted device that could be affected by the tongue stimulation (rare, but reviewed at screening)
• Can commit to 30 to 60 minutes of daily use for 12 weeks

Some people who ask about Lenire are actually better served by a different first step. Two examples: if you have significant hearing loss that has never been treated, a properly fit hearing aid can quiet tinnitus on its own for many patients, and it is a lower-cost starting point. If your tinnitus started right after starting a new medication, changing that medication with your prescribing doctor sometimes resolves the issue.

The candidacy screening at ACI Hearing Center includes a full audiogram, tinnitus severity questionnaires (THI, TFI, or both), a middle-ear function test (tympanometry), a review of your medical and medication history, and a straightforward conversation about what treatment you actually want and can commit to. If we do not think Lenire is your best option, we will tell you and describe what is.

5. The 12-week treatment protocol

Once you are confirmed as a Lenire candidate, treatment runs like this:

6. What clinical trials show about results

Three peer-reviewed clinical trials support Lenire. All three are published in reputable journals and all data is public.

TENT-A1 (Science Translational Medicine, 2020)

The first pivotal trial enrolled 326 adults with chronic subjective tinnitus at sites in Ireland and Germany. Participants used the device for 12 weeks. At the end of the study, more than 80 percent showed clinically meaningful improvement in tinnitus severity, measured by the Tinnitus Handicap Inventory. The improvement held up at 12 months after the treatment ended. Published in Science Translational Medicine (Conlon et al., October 2020).

TENT-A2 (Nature Scientific Reports, 2022)

The second trial refined the stimulation parameters and enrolled a broader patient population. It confirmed durable reductions in tinnitus severity and identified which parameter settings produced the strongest response. This trial is what allowed Neuromod to lock in the exact settings used in the commercial device.

TENT-A3 (Nature Communications, 2024)

The largest and most recent pivotal trial. It ran at multiple sites and compared Lenire against sound therapy alone as an active control. Lenire outperformed sound therapy on the primary and secondary outcome measures. Importantly, 88.6 percent of participants said they would recommend Lenire to treat tinnitus. No device-related serious adverse events were reported. Published in Nature Communications (August 2024). This trial was central to Neuromod's successful FDA De Novo grant.

Honest disclaimer: Not everyone responds. Roughly 15 to 20 percent of trial participants did not see meaningful improvement. Lenire is a treatment, not a cure. If you commit 12 weeks and the numbers do not move, that outcome does happen and we will be straight with you about it.

7. Cost, insurance, and financing

Lenire treatment at ACI Hearing Center is typically $4,000 to $4,500 depending on the bundle. That price covers the device, the personalized sound programming, all provider visits (fitting, week 6, week 12, and week 24 outcome check), the questionnaires and audiograms, and full support during the 12-week protocol.

Insurance coverage right now is limited. Most private insurance plans and Medicare do not yet reimburse Lenire because the device is newer than the codes and coverage decisions that most plans work off. That is changing as more payers add codes, but if you are counting on insurance, call our office first at 337-223-9448 and we will check your specific plan.

Three payment options patients typically use:

• Health savings account (HSA) or flexible spending account (FSA). Lenire is HSA and FSA eligible. This is often the single biggest cost saver because you are paying with pre-tax dollars.
• CareCredit financing. We accept CareCredit for hearing services including Lenire. Typical plans are 6, 12, or 24 months at zero interest for qualified applicants, longer at reduced interest.
• Direct payment. Cash, check, or major credit card at the fitting visit.

8. Side effects and safety

Across the TENT-A1, TENT-A2, and TENT-A3 trials, side effects were mild and short-lived. The most commonly reported were:

• Tongue tingling during and briefly after sessions
• A short-lived metallic or slightly unusual taste
• Mild headache
• Mild dizziness

Most side effects resolved on their own within minutes of ending a session. No serious device-related adverse events were reported in any of the three trials. Lenire does not pierce the skin, does not require surgery, and does not deliver enough current to cause tissue damage at the doses used.

People with certain implanted devices (some cochlear implant configurations, deep brain stimulators, certain cardiac devices) may not be candidates for safety reasons. That gets confirmed at your screening.

9. How Lenire compares to other tinnitus treatments

Tinnitus treatment is not one-size-fits-all. Here is how Lenire fits into the current options.

Treatment	What it does	Typical cost	Best fit
Hearing aids with tinnitus programs	Amplify what you should be hearing, mask tinnitus with soft sound	$2,000 to $7,000/pair	People with hearing loss AND tinnitus (often the first thing to try)
Sound therapy alone	Bedside device or app plays notched or masking sound	$50 to $500	Mild tinnitus, sleep-related tinnitus, budget-limited starting point
Tinnitus retraining therapy (TRT)	Combines sound therapy with counseling over 12 to 24 months	$1,500 to $3,500	Motivated patients, longer time horizon, strong anxiety component
Cognitive behavioral therapy (CBT) for tinnitus	Talk therapy targeting how you react to tinnitus	Insurance-covered mental health rates apply	Tinnitus paired with strong distress, sleep disruption, or anxiety
Lenire	Bimodal neuromodulation, sound + tongue stimulation, 12 weeks	$4,000 to $4,500	Moderate to severe chronic tinnitus, sound therapy alone has not worked, patient is committed to 12 weeks

Many patients benefit from stacking. A common pattern at our office is hearing aids first for anyone with hearing loss, then adding Lenire if the tinnitus is still bothersome after 90 days with well-fit aids.

10. How to get started in Louisiana

ACI Hearing Center in Lafayette is a certified Lenire provider serving the Acadiana region and southern Louisiana. Certified provider status is confirmed on Neuromod's official partner directory at lenire.com/partners. Patients travel to our office from Lafayette, Broussard, Youngsville, Scott, Carencro, Duson, New Iberia, Opelousas, Crowley, Abbeville, and further out.

Getting started takes three steps:

1. Call or book online. Call 337-223-9448 or visit our contact page to request a Lenire candidacy screening. Screenings are typically 60 to 90 minutes.
2. Come in for the screening. Bring a list of current medications and any prior hearing test results. We will do the audiogram, questionnaires, and middle-ear check on the same visit.
3. Review the plan. If you are a candidate, we walk through what treatment will look like, what it will cost, and what payment option works for you. You leave with either a fitting appointment scheduled or a clear recommendation for a different next step.

Ready to schedule? Call 337-223-9448 or email aci@acihearing.com. If you are new to us, our Doctors of Audiology team page has bios and credentials for each provider.

11. Common questions

Is Lenire a hearing aid?

No. Lenire is a tinnitus treatment device, not a hearing aid. It does not amplify sound to help you hear better. Many patients use both, hearing aids for hearing loss and Lenire for tinnitus.

Can I use Lenire while doing other things?

Yes. Most patients use it while reading, working at a desk, or watching TV. It does not require you to sit in silence. Driving is not recommended during sessions.

Do I need a referral from my primary care doctor?

No. Audiology in Louisiana does not require a referral for a candidacy screening. If you are using an HSA or FSA, no referral is needed there either.

What if it does not work for me?

Roughly 15 to 20 percent of trial participants did not see meaningful improvement. If treatment ends at 12 weeks without significant progress, we sit down with you, review your data, and describe alternative approaches. We do not push a second protocol on someone who did not respond to the first.

Do I keep the device after 12 weeks?

Yes. The device stays with you. Many patients continue occasional at-home sessions after the 12-week protocol as needed. There is no rental fee and no recurring subscription.

Can I try Lenire before committing?

The candidacy screening is the trial step. It confirms whether you are likely to benefit. There is no shorter "demo" of the actual treatment because the mechanism depends on the 12-week protocol.

Are there Lenire providers outside Lafayette?

Certified Lenire providers are listed on Neuromod's official directory. ACI Hearing Center is the certified provider serving Acadiana and southern Louisiana. Patients from Baton Rouge, Lake Charles, Alexandria, and further afield travel to our Lafayette office because of provider availability.

How long has ACI Hearing Center been offering Lenire?

ACI Hearing Center has been serving Lafayette and Acadiana since 1984. We became a certified Lenire provider after the March 2023 FDA authorization. All four of our Doctors of Audiology are trained on the protocol.

Sources and further reading

1. U.S. Food and Drug Administration. De Novo classification order for the Lenire Tinnitus Treatment Device (DEN210033), March 2023. accessdata.fda.gov
2. Conlon B, Langguth B, Hamilton C, et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Science Translational Medicine, October 2020. science.org
3. Conlon B, Hamilton C, Meade E, et al. Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Nature Scientific Reports, 2022.
4. Conlon B, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial (TENT-A3). Nature Communications, August 2024. nature.com
5. Neuromod Devices. Lenire clinical trial published in Nature Communications. Company statement, August 2024. neuromod.com
6. Lenire certified provider directory. ACI Hearing Center listing. lenire.com/partners

---